Please assess the completion status of the following clinical trial:

Trial Title: Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Asian males, with benign prostatic hyperplasia (BPH) for at least 6 months prior to initiation and IPSS score greater than or equal to 13 at the beginning of the treatment~* Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED) and overactive bladder (OAB) treatments at any time during the study.~* Have not taken Finasteride or Dutasteride therapy, Anti-androgenic hormone or any other BPH therapy, ED or OAB therapy for specified duration of time prior to the beginning of the treatment~Exclusion Criteria:~* Prostate specific antigen (PSA) score beyond acceptable range defined for study at initiation~* History of urinary retention or lower urinary tract (bladder) stones within 6 months of initiation~* History of urinary urethral obstruction due to stricture, valves, sclerosis, or tumor at initiation~* Clinical evidence of prostate cancer at initiation~* Clinical evidence of any of the bladder or urinary tract conditions, which may affect lower urinary tract symptom at initiation~* History of cardiac conditions, including Angina requiring certain treatment with nitrates, unstable angina defined for study, positive cardiac stress test before starting the study~* History of significant central nervous system injuries (including stroke or spinal cord injury within 6 months of initiation)~* Use of any nitrates, cancer chemotherapy, androgens, antiandrogens, estrogens, luteinizing hormone-releasing hormone (LHRH)agonists/antagonists, or anabolic steroids at initiation

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- 2.5 mg Tadalafil (Type: EXPERIMENTAL): None
- 5.0 mg Tadalafil (Type: EXPERIMENTAL): None
- 0.2 mg Tamsulosin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).